Search results
Added:
1 year ago
EASD 24 - We are joined by Dr Richard Pratley (AdventHealth Diabetes Institute, US) to discuss the kidney, cardiovascular, metabolic, mortality and safety results from the FLOW trial.Interview Questions:1. What is the reasoning behind the FLOW Trial?2. What was the patient population and study design?3. What are the key results?4. Were there any surprising or unexpected findings?5. What further…
View more
Added:
1 year ago
ADA 24 - In this succinct video, we are joined by Dr Vlado Perkovic (UNSW Sydney, Kensington, AU) to discuss a trial investigating the use of semaglutide in patients with type 2 diabetes and chronic kidney disease (NCT03819153).The FLOW trial enrolled 3533 participants with type 2 diabetes and chronic kidney disease, who were then randomized to recieve either semaglutide or placebo. The median…
View more
Added:
1 year ago
THT 24 - We are joined by Dr Firas Zahr (OHSU Knight Cardiovascular Institute Cardiology Clinic, US) to discuss the findings from the ALT FLOW Early Feasibility study (NCT03523416).The ALT FLOW Early Feasibility study aims to assess the initial clinical safety, functionality and effectiveness of a transcatheter atrial shunt system created by Edwards. 75 patients with symptomatic heart failure…
View more
Added:
1 year ago
AHA Conference 2024 — Semaglutide shows increased benefits in CKD patients based on their cardiovascular status and risk profile.Dr Harriette Van Spall (McMaster University, CA) sits down with Dr Katherine Tuttle (University of Washington, US) to discuss the effects of semaglutide in patients with chronic kidney disease (CKD).The FLOW trial (NCT03819153) is designed to assess the effect of…
View more
Added:
8 months ago
EuroPCR 25 - Substudy findings from ILUMIEN-IV show that virtual flow reserve was slightly higher after angiography guidance rather than an optical coherence tomography (OCT)-based physiology assessment after percutaneous coronary intervention (PCI) in high-risk angiographic lesions.We are joined by Dr Thomas Johnson (Bristol Heart Institute, Bristol, UK) to discuss findings from a retrospective…
View more
Added:
8 months ago
EuroPCR 25 - Subgroup analysis outcomes from OCCUPI show optical coherence tomography-guided percutaneous coronary intervention (PCI) is an effective intravascular imaging technique for complex lesions, having successfully met its composite primary outcome measure.We are joined by Dr Byeong-Keuk Kim (Yonsei University College of Medicine, Seoul, KR) to discuss subgroup analysis findings from the…
View more
Added:
1 year ago
LINC 2025 - Outcomes from the GRIFFIN study suggest post-procedural functional flow reserve (FFR) could be a useful predictor of restenosis after drug-coated balloon (DCB) angioplasty for superficial femoral artery (SFA) lesions. Restenosis patients showed significantly lower FFR values than non-restenosis patients, and the study resulted in a good FFR cut-off value of restenosis after DCB…
View more
Shengxian Tu
Research Area(s) / Expertise:
Author
Added:
1 year ago
EuroPCR 24 - We are joined onsite by Dr Carlos Collet (OLV Hospital Aalst, BE) to discuss the findings from a study analysing the influences of the pathophysiological patterns of coronary artery disease on the safety and efficacy of PCI.The study aimed to assess the capacity of pullback pressure gradient (PPG) in predicting post-PCI fractional flow ratio (FFR), as well as the impact of PPG on…
View more
Added:
7 months ago
New York Valves 25 - A substudy of TRISCEND II investigating the effect of transcatheter tricuspid valve replacement (TTVR) on preference-weighted health status showed significant benefits in patients who received TTVR.We are joined by Dr Suzanne Arnold (Saint Luke's Mid America Heart Institute, US) to discuss the findings from a substudy of the TRISCEND II trial, which aimed to create an…
View more